menu
    • menu
    [{"orgOrder":0,"company":"Chong Kun Dang Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Mizoribine","moa":"GMP synthase [glutamine-hydrolyzing] | Inosine-5'-monophosphate dehydrogenase (IMPDH)||Inosine-5\\'-monophosphate dehydrogenase (IMPDH) | GMP synthase [glutamine-hydrolyzing]","graph1":"Immunology","graph2":"Phase II","graph3":"Chong Kun Dang Pharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chong Kun Dang Pharm \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Chong Kun Dang Pharm \/ Undisclosed"},{"orgOrder":0,"company":"Asahi Kasei Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"JAPAN","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Mizoribine","moa":"Inosine-5'-monophosphate dehydrogenase (IMPDH) | GMP synthase [glutamine-hydrolyzing]","graph1":"Nephrology","graph2":"Phase III","graph3":"Asahi Kasei Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Asahi Kasei Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Asahi Kasei Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Asahi Kasei Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"JAPAN","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Mizoribine","moa":"Inosine-5'-monophosphate dehydrogenase (IMPDH) | GMP synthase [glutamine-hydrolyzing]","graph1":"Nephrology","graph2":"Phase III","graph3":"Asahi Kasei Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Asahi Kasei Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Asahi Kasei Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Lee's Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"HONG KONG","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Mizoribine","moa":"Inosine-5'-monophosphate dehydrogenase (IMPDH) | GMP synthase [glutamine-hydrolyzing]","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Lee\\'s Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lee\\'s Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Lee\\'s Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Lee's Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"HONG KONG","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Mizoribine","moa":"Inosine-5'-monophosphate dehydrogenase (IMPDH) | GMP synthase [glutamine-hydrolyzing]","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Lee\\'s Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lee\\'s Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Lee\\'s Pharmaceutical \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for Mizoribine

    Menu

    Mizoribine

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Lee's Pharmaceutical

                            Hong Kong arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Lee's Pharmaceutical

                            Hong Kong arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mizoribine

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Comparative Efficacy of Mizoribine With Mycophenolate Mofetil for Living Related Kidney Transplantation Recipi...

                            Details : Mizoribine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 02, 2023

                            Lead Product(s) : Mizoribine

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Lee's Pharmaceutical

                            Hong Kong arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Lee's Pharmaceutical

                            Hong Kong arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mizoribine

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            An Open Study on the Preventive Effect of Early Mizoribine Conversion on BKV Nephropathy in Renal Transplant R...

                            Details : Mizoribine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 24, 2022

                            Lead Product(s) : Mizoribine

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Asahi Kasei Pharma

                            Japan arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Asahi Kasei Pharma

                            Japan arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mizoribine

                            Therapeutic Area : Nephrology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Evaluate the Efficacy and Safety of Mizoribine in the Treatment of Refractory Nephrotic Syndrome

                            Details : Mizoribine is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Nephrotic Syndrome.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 06, 2014

                            Lead Product(s) : Mizoribine

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Asahi Kasei Pharma

                            Japan arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Asahi Kasei Pharma

                            Japan arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mizoribine

                            Therapeutic Area : Nephrology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Evaluate the Efficacy and Safety of Mizoribine in the Treatment of Lupus Nephritis

                            Details : Mizoribine is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Lupus Nephritis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 03, 2014

                            Lead Product(s) : Mizoribine

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Chong Kun Dang Pharm

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Chong Kun Dang Pharm

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mizoribine

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Safety Study of Mizoribine in Active Rheumatoid (AMOLED)

                            Details : Bredinin is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Arthritis, Rheumatoid.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 09, 2013

                            Lead Product(s) : Mizoribine

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth